nach oben

Erschienen in:

01.04.2015 | Original article

DEGRO practical guidelines for the radiotherapy of non-malignant disorders – Part IV

Symptomatic functional disorders

verfasst von: Dr. med. Gabriele Reinartz, M.D., Hans Theodor Eich, M.D., Fabian Pohl, M.D., German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To summarize the updated DEGRO consensus S2e guideline recommendations for the treatment of benign symptomatic functional disorders with low-dose radiotherapy.

Materials and methods

This overview reports on the role of low-dose radiotherapy in the treatment of functional disorders in cases of heterotopic ossification (HO) and Graves orbitopathy (GO). The most relevant aspects of the DEGRO S2e Consensus Guideline “Radiation Therapy of Benign Diseases 2014” regarding diagnostics, treatment decision, dose prescription, as well as performance of radiotherapy and results are summarized.

Results

For both indications (HO, GO), retrospective and some prospective analyses have shown remarkable effects in terms of symptom relief. Nevertheless, the level of evidence (LoE) and the grade of recommendation (GR) vary: LoE 1–2 and GR A-B (HO), LoE 2 and GR B (GO).

Conclusion

Low-dose radiotherapy for benign symptomatic functional disorders has proven to be effective, according to different authors, for 25–100 % of the patients studied and therefore it may be a reasonable prophylactic and therapeutic option if noninvasive or invasive methods have been used without persistent success.

For HO, a single-fraction dose of 7–8 Gy or fractionated radiation with five fractions of 3.5 Gy is recommended. For GO, single-fraction doses of 0.3–2.0 Gy, and total doses of 2.4–20 Gy/series, applied in one daily fraction are recommended.

American Thyroid Association (1992) Classification of eye changes of Graves’ disease. Thyroid 2:235–236CrossRef

Appelqvist P, Salmo M, Rissanen P (1990) Radiotherapy in emergency treatment of malignant exophthalmos. Strahlenther Onkol 166:190–193PubMed

Banovac K, Sherman AL, Estores IM et al (2004) Prevention and treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med 27:376–382PubMed

Bartalena L, Marcocci C, Manetti L et al (1998) Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 8:439–441CrossRefPubMed

Bossche LV, Vanderstraeten G (2005) Heterotopic ossification: a review. J Rehabil Med 37:129–136CrossRef

Brooker AF, Bowerman JW, Robinson RA et al (1973) Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 55:1629–1632PubMed

Brualla L, Sempau J, Zaragoza FJ et al (2013) Accurate estimation of dose distributions inside an eye irradiated with ¹⁰⁶Ru plaques. Strahlenther Onkol 189:68–73CrossRefPubMed

Burd TA, Lowry KJ, Anglen JO (2001) Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am 83:1783–1788PubMed

Coventry MB, Scanlon PW (1981) The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. J Bone Joint Surg Am 63:201–208PubMed

10.

DeGroot LJ, Gorman CA, Pinchera A et al (1995) Therapeutic controversies. Radiation and Graves’ ophthalmopathy. J Clin Endocrinol Metab 80:339–349PubMed

11.

Eich HT, Micke O, Seegenschmiedt MH (2007) Radiotherapy of Graves’ ophthalmopathy-state of the art and review of the literature. Rontgenpraxis 56:137–144CrossRefPubMed

12.

Friedrich A, Kamprad F, Goldmann A (1997) Clinical importance of radiotherapy in the treatment of Graves’ Disease. In: Wiegel T, Bornfeld N, Foerster MH, Hinkelbein W (eds) Radiotherapy of ocular disease. Front Radiat Ther Oncol. Basel: Karger 30:206–217

13.

Gehl HB, Karstens JH, Casser HR et al (1991) The prevention of ectopic ossification in total hip endoprostheses. Studies on field volume, total dosage and timing of postoperative radiotherapy. Röntgenpraxis 44:117–121PubMed

14.

Giannoudis PV, Grotz MR, Papakostidis C et al (2005) Operative treatment of displaced fractures of the acetabulum. A meta-analysis. J Bone Joint Surg Br 87:2–9PubMed

15.

Gripp S, Doeker R, Glag M et al (2000) Konventionelle und virtuelle Simulation bei der Retrobulbärbestrahlung. Strahlenther Onkol 176:131–134CrossRefPubMed

16.

Heyd R, Buhleier T, Zamboglou N (2009). Radiation therapy for prevention of heterotopic ossification about the elbow. Strahlenther Onkol 185:506–511CrossRefPubMed

17.

Kahaly G, Rösler HP, Pitz S et al (2000) Low versus high dose radiotherapy for Graves ophthalmopathy. J Clin Endocrinol Metab 85:102–108PubMed

18.

Kocher M, Treuer H, Hoevels M et al (2013) Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors. Strahlenther Onkol 189:137–141CrossRefPubMed

19.

Koelbl O, Seufert J, Pohl F et al (2003) Preoperative irradiation for prevention of heterotopic ossification following prosthetic total hip replacement results of a prospective study in 462 hips. Strahlenther Onkol 179:767–773CrossRefPubMed

20.

Kriss JP, Petersen IA, Donaldson SS et al (1989) Supervoltage orbital radiotherapy for progressive Graves’ ophthalmopathy: results of a twenty year experience. Acta Endocrinol (Copenh) 121:154–159

21.

Lo TC, Healy WL (2001). Re-irradiation for prophylaxis of heterotopic ossification after hip surgery. Br J Radiol 74:503–506CrossRefPubMed

22.

Marcocci C, Bartalena L, Panicucci M et al (1987) Orbital cobalt irradiation combined with retrobulbar or systematic cortico-steroids for Graves’ ophthalmopathy: a comparative study. Clin Endocrinol 27:33–42CrossRef

23.

Olivotto IA, Ludgate CM, Allen LH et al (1985) Supervoltage radiotherapy for Graves’ ophthalmopathy: CCABC technique and results. Int J Radiat Oncol Biol Phys 11:2085–2090CrossRefPubMed

24.

van Ouwerkerk BM, Wijngaarde R, Hennemann G (1985). Radiotherapy of severe ophthalmic Graves’ disease. J Endocrinol Invest 8:241–247CrossRefPubMed

25.

Pakos EE, Pitouli EJ, Tsekeris PG et al (2006) Prevention of heterotopic ossification in high-risk patients with total hip arthroplasty: the experience of a combined therapeutic protocol. Int Orthop 30:79–83CrossRefPubMedCentralPubMed

26.

Palmer D, Greenberg P, Cornell P et al (1987) Radiation therapy for Graves’ ophthalmopathy: retrospective analysis. Int J Radiat Oncol Biol Phys 13:1815–1820CrossRefPubMed

27.

Petersen IA, Donaldson SS, McDougall IR et al (1990) Prognostic factors in the radiotherapy of Graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 19:259–264CrossRefPubMed

28.

Pfluger T, Wendt T, Toroutoglou N et al (1990) Retrobulbärbestrahlung bei endokriner Ophthalmopathie: Vergleich zwischen 10 und 16 Gy Herddosis. Strahlenther Onkol 166:673–677PubMed

29.

Prummel MF, Mourits M, Blank L et al (1993) Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342:949–954CrossRefPubMed

30.

Richards AM, Klaassen MF (1997) Heterotopic ossification after severe burns: a report of three cases and review of the literature. Burns 23:64–68CrossRefPubMed

31.

Rosendahl S, Christoffersen JK, Norgaard M (1977) Para-articular ossifications following hip replacement. Acta Orthop Scand 48:400–404CrossRefPubMed

32.

Sandler HM, Rubenstein JH, Fowble BL et al (1989) Results of radiotherapy for thyroid ophthalmopathy. Int J Radiat Oncol Biol Phys 17:823–827CrossRefPubMed

33.

Seegenschmiedt MH, Becker W, Gusek G et al (1995) Megavoltage radiotherapy for severe and refractory progressive Graves’ ophthalmopathy: comparison of scoring systems and long-term results. Int J Radiat Oncol Biol Phys 32:286CrossRef

34.

Seegenschmiedt MH, Keilholz L, Gusek-Schneider G et al (1998) Radiotherapie bei progredienter endokriner Orbitopathie: Langzeitresultate und Klassifikationen im Vergleich. Strahlenther Onkol 174:449–456CrossRefPubMed

35.

Seegenschmiedt MH, Makowski HB, Micke O (2001). German Cooperative Group on Radiotherapy for Benign Diseases. Radiation prophylaxis for heterotopic ossification about the hip joint—a multicenter study. Int J Radiat Biol Phys 51:756–765CrossRef

36.

Staar S, Müller RP, Hammer M et al (1997) Results and prognostic factors in retrobulbar radiotherapy combined with systemic corticosteroids for endocrine orbitopathy (Graves’ Disease). In: Wiegel T, Bornfeld N, Foerster MH, Hinkelbein W (eds) Radiotherapy of ocular disease. Front Radiat Ther Oncol. Basel: Karger, 30:206–217

37.

Stannard JP, Wilson TC, Sheils TM et al (2002) Heterotopic ossification associated with knee dislocation. Arthroscopy 18:835–839CrossRefPubMed

38.

Trott KR (1994). Therapeutic effects of low radiation doses. Strahlenther Onkol 170:1–12PubMed

39.

Uhlenbrock D, Fischer HJ, Rohwerder R (1984) Strahlentherapie der endokrinen Ophthalmopathie—Auswertung von 56 Fällen. Strahlentherapie 160:485–491PubMed

40.

Zeckey C, Hildebrand F, Frink M et al (2011) Heterotopic ossifications following implant surgery-epidemiology, therapeutical approaches and current concepts. Semin Immunopathol 33:273–286CrossRefPubMed

Titel: DEGRO practical guidelines for the radiotherapy of non-malignant disorders – Part IV
Symptomatic functional disorders
verfasst von: Dr. med. Gabriele Reinartz, M.D.
Hans Theodor Eich, M.D.
Fabian Pohl, M.D.
German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD)
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0789-8

Springer Medizin

DEGRO practical guidelines for the radiotherapy of non-malignant disorders – Part IV

Symptomatic functional disorders

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Überlegenheit der IMRT gegenüber der konventionellen 3D-EBRT auch bei der lokalen Kontrolle von Extremitätensarkomen

Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only

Additional androgen deprivation makes the difference

Keine erhöhte Rate an Sekundärmalignomen nach pelviner Radiotherapie

Akzelerierte versus konventionelle Fraktionierung bei der kombinierten Radiochemotherapie von Kopf-Hals-Tumoren

Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie